Participants in APCaRI 01 recruited prediagnosis of prostate cancer
| Number of men in 01 protocol who consented as of 30 June 2019 | 2293 | |
| Prerecruitment biopsy | 76 | (3%) |
| Conversions | 65 | (3%) |
| Completed intake table | 2264 | (99%) |
| Completed BMI value at intake | 2050 | (89%) |
| Completed PSA value at intake | 2259 | (99%) |
| Mean | 10.78 | |
| Median | 6.3 | |
| Range | 0.1–3857.0 | |
| SD | 86.69 | |
| Biopsy not performed | 34 | (1%) |
| Diagnostic prostate biopsy | 2259 | (99%) |
| Biopsy positive for malignancy | 1446 | (64%) |
| Biopsy negative for malignancy | 813 | (36%) |
| Gleason 6 | 410 | (28%) |
| Gleason 7 | 880 | (61%) |
| Gleason ≥8 | 141 | (10%) |
| Missing | 15 | (1%) |
| Radical prostatectomy | 541 | (37%) |
| Cryotherapy | 62 | (4%) |
| Radiation (EBRT) | 287 | (20%) |
| Radiation (Brachy) | 108 | (7%) |
| Chemotherapy | 29 | (2%) |
| Active surveillance | 248 | (17%) |
| Androgen deprivation therapy | 326 | (23%) |
APCaRI, Alberta Prostate Cancer Research Initiative; BMI, body mass index; EBRT, external beam radiation therapy; PSA, prostate specific antigen.